Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26962775 | 1.00 | KDM4E (0.33) | KDM4ESMN1; SMN2CRBNMAPTHDAC1 | |
| SCHEMBL29796749 | 0.89 | GAA (0.36) | CRBN | |
| SCHEMBL26961757 | 0.89 | GAA (0.36) | CRBN | |
| SCHEMBL27119544 | 0.83 | CRBN (0.37) | KDM4ESMN1; SMN2CRBNMAPTHDAC1 | |
| SCHEMBL26961944 | 0.83 | CRBN (0.37) | KDM4ESMN1; SMN2CRBNMAPTHDAC1 | |
| SCHEMBL26961985 | 0.83 | HDAC1 (0.42) | KDM4ESMN1; SMN2MAPTHDAC1HDAC8 | |
| SCHEMBL31628285 | 0.80 | — | — | |
| SCHEMBL31375537 | 0.79 | GAA (0.34) | — | |
| SCHEMBL31628061 | 0.79 | GAA (0.34) | — | |
| SCHEMBL30830313 | 0.79 | GAA (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |